Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener.
NEW YORK (TheStreet) -- Did you miss last night's "Mad Money" on CNBC? If so, here are Jim Cramer's top takeaways for today's trading.
UnitedHealth Group (UNH): With the Federal Reserve set to begin raising interest rates any time now, investors need to stick with secular growth stocks, like the health care cost containment companies. The best of breed player in that group is UnitedHealth.
In addition to being our nation's largest health care provider, UnitedHealth has Optus, its "secret sauce" that includes a pharmacy benefit manager and services company that is expected to contribute up to 40% of UnitedHealth's total earnings in the coming years.
UnitedHealth already puts up huge numbers, but the company is still expected to grow between 9% and 12% a year. Shares of UnitedHealth trade for 17 times earnings, a slight premium to its peers, but Cramer said it deserves that premium and more given its best of breed status and the fact its shares are up 86% over just the past two years.
Ambarella (AMBA): There's no doubt that shares of this semiconductor maker have been on fire of late, with the stock up as much as 150% so far this year. But with the massive selloff of nearly $30 a share in just the past two days, is it time to finally throw in the towel?
The bear case for Ambarella is the company will fall victim to commoditization, is too levered to its largest customer, GoPro (GPRO), and that its valuation is absolutely absurd.
Meanwhile, the bulls say that the company makes the best products for the most lucrative end markets and thus deserves its valuation. Who's right?
Cramer sided with the bulls, saying this video-capture chipmaker is one of only a handful of companies with accelerating revenue growth, or ARG. With shares now trading at just 30 times 2016 earnings, money managers will likely keep paying up for that growth.
Ambarella isn't likely to succumb to commoditization as the company makes only high-end chips and continues to innovate. It's also diversifying itself away from GoPro into very lucrative-end markets like drones, surveillance systems, automotive video and body cameras.
Radius Health (RDUS): In an exclusive interview, Cramer sat down with Bob Ward, president and CEO of Radius Health, a biotech working on a new treatment for osteoporosis. Shares of Radius were up 386% in 2014.
Ward said its new drug, Abaloparatide, is shaping up to be a far superior replacement for Forteo, the current drug offered by Eli Lilly (LLY), which currently has sales to the tune of $1.2 billion a year.
During Radius' 18-month active trial, Ward noted that patients saw zero spinal fractures, a significant feat. He said the key to treating osteoporosis is not waiting until patients reach 70 or 80 years old and facture a big bone, like a hip, but to diagnose them earlier in their 50s.
Abaloparatide is expected to be submitted to the FDA for approval by the end of 2015, with approval expected later in 2016.
To read a full recap of "Mad Money" on CNBC, click here.
To watch replays of Cramer's video segments, visit the Mad Money page on CNBC.
To sign up for Jim Cramer's free Booyah! newsletter with all of his latest articles and videos please click here.